Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Multiple sclerosis
•
Neurology
•
Neuro-immunology
How do you decide between escalation to a high efficacy DMT versus switching to a different moderate efficacy DMT in patients with poorly controlled multiple sclerosis?
Related Questions
Are there any precautions that should be taken when transitioning a patient with multiple sclerosis from one disease modifying therapy to another?
How frequently do you recommend ordering labs to monitor for side effects of disease-modifying therapies for multiple sclerosis?
What are potential pitfalls in the use of OCT to support a diagnosis of multiple sclerosis?
At what degree of lymphopenia do you switch/discontinue dimethyl fumarate in patients with multiple sclerosis?
What criteria do you use to differentiate between MOGAD and MS in pediatric patients?
How would you approach the decision to escalate DMT in a patient with relapsing multiple sclerosis who has two to three new T2 lesion but no clinical symptoms?
What is the role of inebilizumab in the maintenance treatment of IgG4-related disease?
Do you consider steroid-sparing agents for treatment of patients with steroid responsive relapsed Hashimoto Encephalopathy?
What is your initial treatment paradigm for someone with both CNS and peripheral neurologic Sjogren’s?
What is your disease modifying treatment of choice for a patient with relapsing remitting multiple sclerosis with treated, well controlled HIV?
